osteosarcoma

Oncology

In a new pharmaphorum podcast, Paul Romness, president and CEO of OS Therapies, discusses the company's work in osteosarcoma.

News

GSK has claimed its second breakthrough designation from the FDA for B7-H3-targeted ADC, this time in osteosarcoma.

News

A year after its $9.1bn acquisition of Blueprint Medicines, Sanofi is moving out of Blueprint's Cambridge, MA offices and letting 229 employees go.

Digital

A new webinar from Konovo will address some of the critical topics impacting today’s healthcare market research industry.